Glucagonoma syndrome: in vitro evidence that glucagon increases epidermal arachidonic acid.
A 63-year-old white woman with perioral dermatitis, a sore tongue, and an erythematous dermatosis in the inframammary and perineal regions underwent surgical removal of a pancreatic glucagonoma. The patient's plasma and pooled normal human plasma containing Sigma glucagon were fed to human keratinocyte cultures and increased arachidonic acid levels by 300% and 200%, respectively, when compared to pooled normal human plasma with no added commercial glucagon. These experiments suggest that glucagon may increase inflammatory mediators such as arachidonic acid and its metabolites in the epidermis, causing the skin lesions seen in the glucagonoma syndrome.
D007516:Adenoma, Islet Cell / Q000150:complications*; D001095:Arachidonic Acids / Q000378:metabolism*; D004817:Epidermis / Q000378:metabolism*; D004890:Erythema / Q000175:diagnosis / Q000209:etiology*; D005148:Facial Dermatoses / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D005934:Glucagon / Q000502:physiology; D005935:Glucagonoma / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D066298:In Vitro Techniques; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000175:diagnosis; D010502:Perineum; D013577:Syndrome; D013909:Thorax; D014060:Tongue Diseases / Q000175:diagnosis / Q000209:etiology*
D001095:Arachidonic Acids; D005934:Glucagon